Semaglutide

A GLP‑1 receptor agonist with proven ASCVD benefit and strong weight loss is a great candidate drug for patients with cardiovascular disease and obesity. However, it is preferred for HFpEF and it has not been shown to reduce HFrEF hospitalization. It may be added later for weight or ASCVD risk, but it does not replace another cardioprotective drug for HF benefit as a first step.

  • YES [undo]
  • I’m really concerned that this is very hard for you. [undo]
  • MRI [undo]
  • MAC [undo]
  • Υπερκοιλιακή ταχυκαρδία σε δομικά φυσιολογική καρδιά [undo]
  • Οιστρογόνα [undo]
  • Το σωστό είναι 1,77 m; [undo]
  • Lymph Nodes sample [undo]
  • The NCCT scan [undo]
  • Assign a coordinator but without explaining roles [undo]
  • Έλεγχος νεφρικής λειτουργίας [undo]
  • Επιπλέον ιστορικό [undo]
  • His Child [undo]
  • Δεν υπάρχει ένδειξη καρωτιδικής επέμβασης, προχωρούμε σε αορτολαγόνια επέμβαση [undo]
  • Νοσοκομείο [undo]
  • Semaglutide [undo]

Map: Michael Green_GEMD_2 (1116)
Node: 21124
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway